195 related articles for article (PubMed ID: 24164099)
1. Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.
Rehman K; Naranmandura H
Curr Drug Metab; 2013 Dec; 14(10):1029-41. PubMed ID: 24164099
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
4. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
5. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
Zhao WL; Chen SJ; Shen Y; Xu L; Cai X; Chen GQ; Shen ZX; Chen Z; Wang ZY
Leuk Lymphoma; 2001; 42(6):1265-73. PubMed ID: 11911407
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
Chen Z; Wang ZY; Chen SJ
Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
[TBL] [Abstract][Full Text] [Related]
8. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
12. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, toxicity and anticancer activities of arsenic compounds.
Khairul I; Wang QQ; Jiang YH; Wang C; Naranmandura H
Oncotarget; 2017 Apr; 8(14):23905-23926. PubMed ID: 28108741
[TBL] [Abstract][Full Text] [Related]
15. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
19. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]